VIRX Viracta Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VIRX

Price (delayed)

$0.8102

Market cap

$31.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.32

Enterprise value

$45.06M

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination ...

Highlights
The quick ratio has dropped by 85% year-on-year and by 19% since the previous quarter
The equity has plunged by 70% YoY and by 39% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.viracta.com
Peers: OMER OMGA

Key stats

What are the main financial stats of VIRX
Market
Shares outstanding
39.27M
Market cap
$31.82M
Enterprise value
$45.06M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.71
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$47.35M
EBITDA
-$46.86M
Free cash flow
-$40.03M
Per share
EPS
-$1.32
Free cash flow per share
-$1.04
Book value per share
$0.47
Revenue per share
$0
TBVPS
$1.47
Balance sheet
Total assets
$56.69M
Total liabilities
$38.37M
Debt
$25.56M
Equity
$18.32M
Working capital
$16.59M
Liquidity
Debt to equity
1.4
Current ratio
1.43
Quick ratio
1.4
Net debt/EBITDA
-0.28
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-71.5%
Return on equity
-145.6%
Return on invested capital
-82.8%
Return on capital employed
-258.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VIRX stock price

How has the Viracta Therapeutics stock price performed over time
Intraday
-3.55%
1 week
-2.39%
1 month
-25.67%
1 year
-28.3%
YTD
42.14%
QTD
-20.57%

Financial performance

How have Viracta Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$50.69M
Net income
-$51.06M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 7% from the previous quarter and by 3.8% YoY
The operating income has declined by 4.1% since the previous quarter

Growth

What is Viracta Therapeutics's growth rate over time

Valuation

What is Viracta Therapeutics stock price valuation
P/E
N/A
P/B
1.71
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
VIRX's EPS is down by 6% from the previous quarter
The equity has plunged by 70% YoY and by 39% from the previous quarter
The stock's price to book (P/B) is 32% more than its last 4 quarters average of 1.3 but 10% less than its 5-year quarterly average of 1.9

Efficiency

How efficient is Viracta Therapeutics business performance
The ROE has plunged by 116% YoY and by 40% from the previous quarter
The return on invested capital is up by 41% year-on-year but it has declined by 26% since the previous quarter
The return on assets has declined by 33% year-on-year and by 22% since the previous quarter

Dividends

What is VIRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VIRX.

Financial health

How did Viracta Therapeutics financials performed over time
The company's total assets is 48% higher than its total liabilities
The quick ratio has dropped by 85% year-on-year and by 19% since the previous quarter
VIRX's current ratio has dropped by 85% year-on-year and by 19% since the previous quarter
The company's debt is 40% higher than its equity
The equity has plunged by 70% YoY and by 39% from the previous quarter
Viracta Therapeutics's debt to equity has surged by 65% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.